Short Interest in Delcath Systems, Inc. (NASDAQ:DCTH) Drops By 20.5%

Delcath Systems, Inc. (NASDAQ:DCTH) saw a significant drop in short interest in the month of February. As of February 28th, there was short interest totalling 700,600 shares, a drop of 20.5% from the February 13th total of 881,500 shares. Based on an average trading volume of 401,400 shares, the days-to-cover ratio is currently 1.7 days. Currently, 2.7% of the company’s shares are sold short.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the stock. HC Wainwright boosted their price objective on shares of Delcath Systems from $22.00 to $24.00 and gave the stock a “buy” rating in a research note on Friday, March 7th. Craig Hallum lifted their price target on shares of Delcath Systems from $18.00 to $21.00 and gave the stock a “buy” rating in a research note on Friday, January 17th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $22.75.

Institutional Investors Weigh In On Delcath Systems

A number of institutional investors have recently added to or reduced their stakes in DCTH. Principal Financial Group Inc. purchased a new stake in Delcath Systems in the third quarter valued at $808,000. Baader Bank Aktiengesellschaft acquired a new stake in shares of Delcath Systems in the fourth quarter worth approximately $204,000. Barclays PLC purchased a new stake in shares of Delcath Systems during the third quarter worth $104,000. Jane Street Group LLC acquired a new position in shares of Delcath Systems during the 3rd quarter worth approximately $110,000. Finally, Private Advisor Group LLC purchased a new stake in Delcath Systems in the 4th quarter valued at $153,000. Institutional investors own 61.12% of the company’s stock.

Delcath Systems Stock Up 4.1 %

Shares of NASDAQ:DCTH opened at $12.58 on Monday. Delcath Systems has a 52 week low of $3.93 and a 52 week high of $16.97. The firm has a fifty day simple moving average of $14.40 and a two-hundred day simple moving average of $11.82. The stock has a market capitalization of $420.21 million, a P/E ratio of -9.32 and a beta of 0.82.

Delcath Systems (NASDAQ:DCTH) last posted its quarterly earnings data on Thursday, March 6th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01). The business had revenue of $15.10 million for the quarter, compared to analysts’ expectations of $14.96 million. Delcath Systems had a negative net margin of 150.70% and a negative return on equity of 338.16%. During the same quarter in the previous year, the firm earned ($0.48) EPS. On average, analysts expect that Delcath Systems will post -0.79 earnings per share for the current year.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.